CV Sciences, Inc. (CVSI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CV Sciences, Inc. (CVSI) with AI Score 42/100 (Weak). CV Sciences, Inc. operates as a life science company focused on plant-based dietary supplements and pharmaceutical cannabinoid development. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026CV Sciences, Inc. (CVSI) Healthcare & Pipeline Overview
CV Sciences, Inc. develops and markets hemp-based CBD products and plant-based dietary supplements under brands like PlusCBD, targeting the nutraceutical, beauty, and pet sectors. It also develops cannabinoid-based pharmaceuticals, positioning itself in both the consumer wellness and specialty drug markets within the healthcare industry.
Investment Thesis
CV Sciences, Inc. presents a speculative investment thesis centered on its dual approach to the cannabinoid market through consumer products and pharmaceutical development. The company's established consumer product lines, generating a gross margin of 47.0%, provide a revenue base to fund its pharmaceutical endeavors. The development of CVSI-007, targeting smokeless tobacco addiction, represents a high-risk, high-reward opportunity. The company's small market capitalization of $0.01 billion and negative P/E ratio of -4.99 indicate substantial risk. Successful clinical trials and subsequent commercialization of CVSI-007 could drive significant value. However, regulatory hurdles, competition, and the need for additional capital are potential risks. Investors should closely monitor clinical trial outcomes, regulatory developments, and the company's ability to maintain market share in the competitive CBD consumer product market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion, reflecting its status as a micro-cap company.
- Negative P/E ratio of -4.99, indicating that the company is currently unprofitable.
- Gross margin of 47.0%, showcasing the potential profitability of its consumer product segment.
- Beta of 0.19, suggesting lower volatility compared to the overall market.
- Focus on developing CVSI-007, a pharmaceutical drug candidate for smokeless tobacco addiction, highlighting its commitment to innovation.
Competitors & Peers
Strengths
- Established brand presence in the CBD market.
- Diverse product portfolio across multiple health sectors.
- Dual focus on consumer products and pharmaceutical development.
- Proprietary drug candidate CVSI-007.
Weaknesses
- Small market capitalization and limited financial resources.
- Negative profitability and reliance on external funding.
- Dependence on regulatory environment for CBD products.
- Limited market share compared to larger competitors.
Catalysts
- Upcoming: Clinical trial results for CVSI-007 in smokeless tobacco addiction treatment.
- Ongoing: Expansion of the PlusCBD product line into new retail channels.
- Ongoing: Development of new CBD-based products for specific health conditions.
- Ongoing: Geographic expansion into international markets.
- Ongoing: Potential strategic acquisitions of complementary businesses.
Risks
- Potential: Regulatory changes impacting the CBD market.
- Potential: Delays or failures in clinical trials for CVSI-007.
- Ongoing: Intense competition in the CBD market.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Fluctuations in raw material prices.
Growth Opportunities
- Expansion of the PlusCBD product line into new retail channels: CV Sciences can expand its reach by securing partnerships with major retail chains and online marketplaces. The global nutraceutical market is projected to reach $441.7 billion by 2026, offering a significant opportunity for increased sales. Timeline: Ongoing.
- Development and commercialization of CVSI-007: Successful clinical trials and regulatory approval of CVSI-007 for smokeless tobacco addiction could create a significant revenue stream. The market for smoking cessation products is estimated at $8.7 billion globally. Timeline: 3-5 years, contingent on clinical trial results and regulatory approvals.
- Geographic expansion into international markets: CV Sciences can explore opportunities to expand its consumer product sales into international markets, particularly in Europe and Asia, where the demand for CBD products is growing. The European CBD market is projected to reach $1.5 billion by 2027. Timeline: 2-3 years.
- Strategic acquisitions of complementary businesses: CV Sciences can consider acquiring smaller companies with innovative products or technologies in the CBD or nutraceutical space to expand its product portfolio and market reach. The M&A activity in the cannabis industry remains active. Timeline: Opportunistic.
- Development of new CBD-based products for specific health conditions: CV Sciences can invest in research and development to create new CBD-based products targeting specific health conditions, such as anxiety, sleep disorders, and pain management. The market for CBD-based health products is expanding rapidly. Timeline: Ongoing.
Opportunities
- Expansion into new geographic markets.
- Development of new CBD-based products for specific health conditions.
- Strategic partnerships and acquisitions.
- Successful commercialization of CVSI-007.
Threats
- Intense competition in the CBD market.
- Regulatory uncertainty and potential changes in CBD regulations.
- Fluctuations in raw material prices.
- Potential delays or failures in clinical trials for CVSI-007.
Competitive Advantages
- Established brand recognition with PlusCBD and other brands.
- Proprietary formulations and manufacturing processes.
- Focus on both consumer products and pharmaceutical development.
- Distribution network through multiple channels.
About CVSI
CV Sciences, Inc., established in 2010 and based in San Diego, California, operates as a life science company in North America. Initially known as CannaVest Corp., the company rebranded in January 2016 to reflect its focus on cannabinoid-based products. CV Sciences is structured into two primary segments: Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under various brand names, including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. These products cater to diverse health care sectors, including nutraceuticals, beauty care, specialty foods, and pet products. The company distributes its consumer products through its websites, internet sales channels, select distributors, brick-and-mortar retailers, and e-tailers. The Specialty Pharmaceutical segment is dedicated to the development and commercialization of cannabinoids for treating medical indications. Its lead drug candidate, CVSI-007, combines CBD and nicotine for the treatment of smokeless tobacco use and addiction, representing the company's foray into pharmaceutical applications of cannabinoids. CV Sciences aims to leverage its expertise in both consumer wellness and pharmaceutical development to establish a strong presence in the cannabinoid market.
What They Do
- Develops and markets plant-based dietary supplements.
- Manufactures and sells hemp-based cannabidiol (CBD) products.
- Operates in the nutraceutical, beauty care, specialty foods, and pet product sectors.
- Sells products through websites, internet sales, distributors, retailers, and e-tailers.
- Develops cannabinoid-based pharmaceuticals for medical indications.
- Focuses on CVSI-007, a drug candidate for smokeless tobacco addiction.
Business Model
- Develops and manufactures CBD and plant-based products.
- Sells products directly to consumers through online channels.
- Distributes products through retail partnerships.
- Develops pharmaceutical drugs based on cannabinoids.
Industry Context
CV Sciences operates within the rapidly evolving cannabis and CBD industry. The market is characterized by increasing consumer acceptance of CBD products for wellness applications and growing interest in cannabinoid-based pharmaceuticals. The industry faces regulatory uncertainty and intense competition from both established players and new entrants. CV Sciences' dual focus on consumer products and pharmaceutical development positions it to capitalize on both the immediate demand for CBD products and the long-term potential of cannabinoid-based therapies. Competitors include companies like AUSAF, AYRWF, AYURF, BQST, and BUDZ, all vying for market share in the cannabis and CBD space.
Key Customers
- Consumers seeking plant-based dietary supplements.
- Individuals interested in hemp-based CBD products for wellness.
- Retailers and distributors in the nutraceutical and beauty industries.
- Patients seeking cannabinoid-based pharmaceuticals (future).
Financials
Chart & Info
CV Sciences, Inc. (CVSI) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Dec 6, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CVSI.
Price Targets
Wall Street price target analysis for CVSI.
MoonshotScore
What does this score mean?
The MoonshotScore rates CVSI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Joseph D. Dowling
Unknown
Information on Joseph D. Dowling's background is not available in the provided context. Further research would be needed to provide details on his career history, education, and previous roles.
Track Record: Information on Joseph D. Dowling's track record is not available in the provided context. Further research would be needed to provide details on key achievements, strategic decisions, and company milestones under his leadership.
CVSI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CV Sciences, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Lower trading volume and liquidity compared to listed stocks.
- Potential for price manipulation and fraud.
- Higher risk of delisting or trading suspension.
- Greater difficulty in obtaining accurate and timely information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and funding needs.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Established business operations with a history of revenue generation.
- Presence of a functioning website and investor relations materials.
- Independent auditor review of financial statements (if available).
- Active engagement with shareholders and the investment community.
- Development of a proprietary drug candidate (CVSI-007).
CV Sciences, Inc. Stock: Key Questions Answered
What does CV Sciences, Inc. do?
CV Sciences, Inc. operates as a life science company focused on the development, manufacturing, and marketing of plant-based dietary supplements and hemp-based cannabidiol (CBD) products. The company's Consumer Products segment offers a range of CBD products under brands like PlusCBD, targeting the nutraceutical, beauty, and pet sectors. Additionally, the Specialty Pharmaceutical segment is developing CVSI-007, a drug candidate combining CBD and nicotine for the treatment of smokeless tobacco use and addiction. CV Sciences aims to leverage its expertise in both consumer wellness and pharmaceutical development.
What do analysts say about CVSI stock?
As of 2026-03-16, a comprehensive analyst consensus on CVSI stock is unavailable due to its OTC listing and limited coverage. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability. Growth considerations center on the successful development and commercialization of CVSI-007 and the expansion of its consumer product lines. Investors should conduct their own due diligence and consider the inherent risks associated with micro-cap OTC stocks in the cannabis industry.
What are the main risks for CVSI?
The main risks for CV Sciences, Inc. include regulatory uncertainty surrounding CBD products, intense competition in the CBD market, and the potential for delays or failures in clinical trials for CVSI-007. The company's limited financial resources and reliance on external funding also pose a risk. As an OTC-listed company, CVSI faces additional risks related to liquidity, disclosure, and regulatory oversight. Investors should carefully consider these risks before investing in CVSI.
What are the key factors to evaluate for CVSI?
CV Sciences, Inc. (CVSI) currently holds an AI score of 42/100, indicating low score. Key strength: Established brand presence in the CBD market.. Primary risk to monitor: Potential: Regulatory changes impacting the CBD market.. This is not financial advice.
How frequently does CVSI data refresh on this page?
CVSI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CVSI's recent stock price performance?
Recent price movement in CV Sciences, Inc. (CVSI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brand presence in the CBD market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CVSI overvalued or undervalued right now?
Determining whether CV Sciences, Inc. (CVSI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CVSI?
Before investing in CV Sciences, Inc. (CVSI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited or less reliable than exchange-listed data.
- AI analysis pending for CVSI.